News

The technology includes analyzing gene expression change in RNA extracted from the bulb of cells located at the base of a single human plucked hair. The companies have

Under the terms of a supply agreement, Merck will manufacture and supply the alendronate sodium tablets to Watson, which will market, sell and distribute the product in the

Dan McMahon, director of marketing, CytoCore, said: “We are in the final stages of completing the North American distribution organization and expect to be able to launch the

The Nucleonics’s HBV clinical candidate (NUC B1000) is an expressed interfering RNA (eiRNA) based product, consisting of a plasmid DNA construct that encodes four short interfering RNA (siRNA)

The total deal, valued at up to $9.65 million, provides for the formation of a 50/50 joint venture entity that will own, develop and secure a commercialization partner

Under the terms of the agreement, Agilent will make an undisclosed settlement payment to Invitrogen. In addition, Agilent will discontinue sales of its RNase H minus RT products

Under the regulation, a paediatric investigation plan, or PIP, must accompany all new product approval applications in the EU from July 26, 2008. The same applies to applications

The open label trial was designed to assess the safety and pharmacokinetic profile of Thallion’s new continuous intravenous formulation of CAP-232, as well as provide efficacy data in

According to the Department of Health, the new guidance has been designed to provide advice on how primary care trusts, pharmaceutical companies and clinicians can work side by